AAAAAA

   
Results: 1-18 |
Results: 18
New insights in medical mycology: Focus on fungal infections - Introduction
Authors: Klepser, ME
Citation: Me. Klepser, New insights in medical mycology: Focus on fungal infections - Introduction, PHARMACOTHE, 21(8), 2001, pp. 109S-110S
Antifungal resistance among Candida species
Authors: Klepser, ME
Citation: Me. Klepser, Antifungal resistance among Candida species, PHARMACOTHE, 21(8), 2001, pp. 124S-132S
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model
Authors: Klepser, ME Ernst, EJ Petzold, CR Rhomberg, P Doern, GV
Citation: Me. Klepser et al., Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model, ANTIM AG CH, 45(3), 2001, pp. 673-678
Novel triazole antifungal agents
Authors: Hoffman, HL Ernst, EJ Klepser, ME
Citation: Hl. Hoffman et al., Novel triazole antifungal agents, EXPERT OP I, 9(3), 2000, pp. 593-605
Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection
Authors: Lewis, RE Klepser, ME Ernst, EJ Snabes, MA Jones, RN
Citation: Re. Lewis et al., Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection, DIAG MICR I, 37(1), 2000, pp. 51-55
In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods
Authors: Lewis, RE Klepser, ME Pfaller, MA
Citation: Re. Lewis et al., In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods, DIAG MICR I, 36(2), 2000, pp. 101-105
Comparison of the serum and intracellular pharmacokinetics of azithromycinin healthy and diabetic volunteers
Authors: Ernst, EJ Klepser, ME Klepser, TB Nightingale, CH Hunsicker, LG
Citation: Ej. Ernst et al., Comparison of the serum and intracellular pharmacokinetics of azithromycinin healthy and diabetic volunteers, PHARMACOTHE, 20(6), 2000, pp. 657-661
Assessment of patients' perceptions and beliefs regarding herbal therapies
Authors: Klepser, TB Doucette, WR Horton, MR Buys, LM Ernst, ME Ford, JK Hoehns, JD Kautzman, HA Logemann, CD Swegle, JM Ritho, M Klepser, ME
Citation: Tb. Klepser et al., Assessment of patients' perceptions and beliefs regarding herbal therapies, PHARMACOTHE, 20(1), 2000, pp. 83-87
Evaluation of voriconazole pharmacodynamics using time-kill methodology
Authors: Klepser, ME Malone, D Lewis, RE Ernst, EJ Pfaller, MA
Citation: Me. Klepser et al., Evaluation of voriconazole pharmacodynamics using time-kill methodology, ANTIM AG CH, 44(7), 2000, pp. 1917-1920
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans
Authors: Ernst, EJ Klepser, ME Pfaller, MA
Citation: Ej. Ernst et al., Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans, ANTIM AG CH, 44(4), 2000, pp. 1108-1111
In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect
Authors: Gunderson, SM Hoffman, H Ernst, EJ Pfaller, MA Klepser, ME
Citation: Sm. Gunderson et al., In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect, ANTIM AG CH, 44(10), 2000, pp. 2887-2890
The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy
Authors: Lewis, RE Klepser, ME
Citation: Re. Lewis et Me. Klepser, The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy, AM J HEAL S, 56(6), 1999, pp. 525-533
Unsafe and potentially safe herbal therapies
Authors: Klepser, TB Klepser, ME
Citation: Tb. Klepser et Me. Klepser, Unsafe and potentially safe herbal therapies, AM J HEAL S, 56(2), 1999, pp. 125-138
Role of the newer fluoroquinolones against penicillin-resistant Streptococcus pneumoniae
Authors: Appelbaum, PC Klepser, ME
Citation: Pc. Appelbaum et Me. Klepser, Role of the newer fluoroquinolones against penicillin-resistant Streptococcus pneumoniae, INF DIS C P, 8(8), 1999, pp. 374-382
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
Authors: Ernst, EJ Klepser, ME Ernst, ME Messer, SA Pfaller, MA
Citation: Ej. Ernst et al., In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods, DIAG MICR I, 33(2), 1999, pp. 75-80
Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection
Authors: Lewis, RE Klepser, ME Ernst, EJ Lund, BC Biedenbach, DJ Jones, RN
Citation: Re. Lewis et al., Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection, ANTIM AG CH, 43(8), 1999, pp. 2005-2009
Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options
Authors: Klepser, ME Lewis, RE Pfaller, MA
Citation: Me. Klepser et al., Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options, ANN PHARMAC, 32(12), 1998, pp. 1353-1361
In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: Effect of concentration and exposure time
Authors: Ernst, EJ Klepser, ME Pfaller, MA
Citation: Ej. Ernst et al., In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: Effect of concentration and exposure time, DIAG MICR I, 32(3), 1998, pp. 205-210
Risultati: 1-18 |